Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...

The rapid addition of small interfering RNA therapy to usual care after a recent ACS helps more patients achieve recommended ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

Three Motley Fool contributors believe they've found no-brainer healthcare stocks to buy in June. (Amgen): One of the best ...